Archive: Company News
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material for IOS-1002, ImmunOs’ lead program for the treatment of cancer. ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs’ innovative biologic.
EBViously Announces First Details of Its EBV-001 Vaccine Candidate for the Prevention of Epstein-Barr Virus (EBV)-Induced Diseases
— Presentation at the World Vaccine Congress 2023
— EBV-infections associated with many cancers and multiple sclerosis
EBViously, a start-up developing novel vaccines based on next-generation virus-like particles, will present its approach and technology at the upcoming World Vaccine Congress 2023 (April 4-6, 2023) in Washington, DC (USA). The presentation will take place on Wednesday, April 5, 2023, at 2:55 p.m. EST in Room 201 of the Walter E. Washington Convention Center in Washington, DC.
InfanDx AG Revises Strategy and Broadens Diagnostics Pipeline for Child Health
— After promising top-line data for metabolic biomarkers, in-depth data analysis revealed BANON study results not generalizable to HIE patients in clinical routine.
— Development of HypoxE® test based purely on metabolic biomarkers discontinued accordingly.
— Shareholders unanimously approve expansion of business strategy into new areas of pediatric health care.
InfanDx AG, a privately held company focusing on the development and commercialization of novel diagnostic solutions for child health, today announced a strategic repositioning of the Company by broadening its pipeline of innovative solutions for child health.
Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001
– Novel compound for targeted tumor therapy to be evaluated in patients with soft tissue sarcoma
– First patients to be enrolled in Q2, 2023
Thermosome, a drug development company specializing in targeted tumor therapies, today announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible Ethics Committee to conduct a Phase 1 trial with its lead program THE001 in Germany. Patient enrollment is expected to start in Q2, 2023.
The primary endpoints of the Phase 1, open-label, interventional dose-escalation study are the safety and tolerability of THE001 and the determination of the maximum tolerated dose. A secondary objective is to evaluate anti-tumor activity. Read more…